Skip to Main Content

Author Details

Daniel S Peeper
Netherlands Cancer Institute
1987
133
54
PMIDPaper TitleJournal TitlePublished Year
36715448TSC2 regulates tumor susceptibility to TRAIL-mediated T-cell killing by orchestrating mTOR signaling.EMBO J2023
37398651Heterogeneity in functional genetic screens: friend or foe?Front Immunol2023
36753617The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma.Mol Cancer Res2023
36753604Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.Cancer Immunol Res2023
36788428Acidity-mediated induction of FoxP3<sup>+</sup> regulatory T cells.Eur J Immunol2023
36750559Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.Nat Commun2023
36920329IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.J Exp Med2023
36812891An adverse tumor-protective effect of IDO1 inhibition.Cell Rep Med2023
36545919MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.Melanoma Res2023
34930786Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.Cancer Discov2022
35840685Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.Nature2022
35395848Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.Nat Commun2022
35688159RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.Cell Rep Med2022
36465485<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.Oncoimmunology2022
35264796Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.Nature2022
33328638Anti-tumour immunity induces aberrant peptide presentation in melanoma.Nature2021
35756970The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens.Immunooncol Technol2021
33576875Metabolic profiles of regulatory T cells in the tumour microenvironment.Cancer Immunol Immunother2021
33558721Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.Nat Med2021
33531370Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.Cancer Res2021
34937871Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.Nat Commun2021
34516853Enabling oncogenes.Science2021
34562372Oncogene-dependent sloppiness in mRNA translation.Mol Cell2021
34343000Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells.J Proteome Res2021
34230026Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.Clin Cancer Res2021
31549767A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma.Pigment Cell Melanoma Res2020
31772060Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux.Mol Cell Proteomics2020
31978349Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.Cell2020
31942075B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020
33262254Comprehensive analysis of cutaneous and uveal melanoma liver metastases.J Immunother Cancer2020
32770055Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.Nat Commun2020
32620126Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.J Transl Med2020
32187553FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice.Cell Rep2020
32467386The human tumor microbiome is composed of tumor type-specific intracellular bacteria.Science2020
32271879Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.J Exp Med2020
32559422Rational Cancer Treatment Combinations: An Urgent Clinical Need.Mol Cell2020
30674724Frequent clonal relations between metastases and non-index prostate cancer lesions.JCI Insight2019
31303383Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.Cell2019
31270153<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma.Mol Cancer Ther2019
31521607High-Throughput Assessment of Kinome-wide Activation States.Cell Syst2019
31160251Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.Lancet Oncol2019
31125352Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.PLoS One2019
31160710Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.Nat Cell Biol2019
29334371Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Nat Med2018
30464211Integrative epigenetic taxonomy of primary prostate cancer.Nat Commun2018
30297911Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.Nat Med2018
30286710XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.BMC Bioinformatics2018
29634951Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.Cancer Cell2018
29438700Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.Cancer Cell2018
29507054Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.Mol Syst Biol2018
  • 1 - 50 of 133

Recommended Authors

Shruthy Suresh
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 6
Juan L Callejas-Valera
Cancer Biology Research Center
Career Start Year 2008
Number of shared co-authors 1
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 8
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 3
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 6
Andrew V Kossenkov
The Wistar Institute
Career Start Year 2003
Number of shared co-authors 7
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 3
Yongmei Feng
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2002
Number of shared co-authors 5
Chi-Ping Day
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 7
Daniel Zingg
Netherlands Cancer Institute
Career Start Year 2001
Number of shared co-authors 5
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 2
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Career Start Year 1996
Number of shared co-authors 7
Michael A White
University of Georgia
Career Start Year 1994
Number of shared co-authors 1
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 3
Andrei Goga
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 4
Jan Paul Medema
Oncode Institute
Career Start Year 1993
Number of shared co-authors 7
Ashani T Weeraratna
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Career Start Year 1992
Number of shared co-authors 12
Marcus Bosenberg
Yale School of Medicine
Career Start Year 1992
Number of shared co-authors 13
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 13
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 5
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 2
Eldad Zacksenhaus
University of Toronto
Career Start Year 1988
Number of shared co-authors 0
Lori S Hart
Children's Hospital of Philadelphia, USA. [2] Center for Childhood Cancer Research
Career Start Year 1987
Number of shared co-authors 4
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 13
Ze'ev Ronai
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 1981
Number of shared co-authors 9
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 10
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 22

Collaborators

Oscar Krijgsman
The Netherlands Cancer Institute
Co-authored papers 36
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 20
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 10
Albert J R Heck
Utrecht University
Co-authored papers 6
Emile E Voest
The Netherlands Cancer Institute
Co-authored papers 6
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 5
David J Adams
Wellcome Sanger Institute
Co-authored papers 5
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 4
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 4
Georgina V Long
Co-authored papers 4
Oscar M Rueda
University of Cambridge
Co-authored papers 4
Yardena Samuels
Weizmann Institute of Science
Co-authored papers 4
Richard A Scolyer
Co-authored papers 4
Annette T Byrne
Royal College of Surgeons in Ireland (RCSI)
Co-authored papers 3
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Co-authored papers 3
Jennifer A Wargo
Co-authored papers 3
Emilie Vinolo
CNRS URA 5
Co-authored papers 3
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 3
Els Hermans
Netherlands Cancer Institute
Co-authored papers 3
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 3
Fr??d??ric Amant
Netherlands Cancer Institute
Co-authored papers 3
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 3
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 3
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Co-authored papers 2
Martijn P Lolkema
Erasmus MC Cancer Institute
Co-authored papers 2
Elisabetta Marangoni
Co-authored papers 2
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Co-authored papers 2
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 2
Abdel G Elkahloun
National Human Genome Research Institute
Co-authored papers 2
Release 1.2